PDS Biotechnology Set to Release Q2 2025 Earnings: What Investors Need to Know
PorAinvest
martes, 12 de agosto de 2025, 7:41 pm ET1 min de lectura
PDSB--
PDS Biotechnology (PDSB) is poised to release its quarterly earnings report on August 13, 2025. Analysts estimate an earnings per share (EPS) of $-0.24, but the company has a history of beating EPS estimates. In the last quarter, PDS Biotechnology reported an EPS of $-0.21, which was $0.04 higher than the estimated $-0.25 [1].
This past performance has resulted in a 3.05% increase in share price the next day. However, long-term shareholders are likely displeased with the 60.6% decline in shares over the last 52 weeks. The stock has been highly volatile, with significant fluctuations in price. On August 12, 2025, the stock gained 13.89%, rising from $1.08 to $1.23 [2].
Analysts and investors are closely watching the earnings report for both earnings performance and guidance for the next quarter. While earnings performance is crucial, market reactions are often driven by guidance. Historical data suggests that positive guidance can lead to significant price movements.
The stock is currently trading at $1.08, and it is expected to open at $1.18 on August 13, 2025, with a possible trading interval of $1.19 to $1.27. This gives a possible move of 7.12% during the day. The stock is considered a buy candidate due to several short-term positive signals, despite being in a falling trend [2].
References:
1. [1] https://www.benzinga.com/insights/earnings/25/08/47069695/insights-into-pds-biotechnologys-upcoming-earnings
2. [2] https://stockinvest.us/stock/PDSB
PDS Biotechnology is set to release its quarterly earnings report on August 13. Analysts estimate an EPS of $-0.24. The company has a history of beating EPS estimates, which has led to a 3.05% increase in share price the next day. Long-term shareholders are likely upset given the 60.6% decline in shares over the last 52 weeks.
Title: PDS Biotechnology: Upcoming Earnings Report and Market ExpectationsPDS Biotechnology (PDSB) is poised to release its quarterly earnings report on August 13, 2025. Analysts estimate an earnings per share (EPS) of $-0.24, but the company has a history of beating EPS estimates. In the last quarter, PDS Biotechnology reported an EPS of $-0.21, which was $0.04 higher than the estimated $-0.25 [1].
This past performance has resulted in a 3.05% increase in share price the next day. However, long-term shareholders are likely displeased with the 60.6% decline in shares over the last 52 weeks. The stock has been highly volatile, with significant fluctuations in price. On August 12, 2025, the stock gained 13.89%, rising from $1.08 to $1.23 [2].
Analysts and investors are closely watching the earnings report for both earnings performance and guidance for the next quarter. While earnings performance is crucial, market reactions are often driven by guidance. Historical data suggests that positive guidance can lead to significant price movements.
The stock is currently trading at $1.08, and it is expected to open at $1.18 on August 13, 2025, with a possible trading interval of $1.19 to $1.27. This gives a possible move of 7.12% during the day. The stock is considered a buy candidate due to several short-term positive signals, despite being in a falling trend [2].
References:
1. [1] https://www.benzinga.com/insights/earnings/25/08/47069695/insights-into-pds-biotechnologys-upcoming-earnings
2. [2] https://stockinvest.us/stock/PDSB
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios